The FDA recently approved Signos’ innovative glucose monitoring system designed specifically for weight loss. This marks a significant step for many Americans seeking effective ways to manage their weight.
Traditionally, weight-loss treatments like GLP-1 medications—such as Wegovy and Zepbound—are available primarily to individuals with obesity or specific BMI criteria. They can also be quite expensive, and access may be limited through insurance. Now, with Signos, anyone looking to shed some pounds can join a membership and get started.
Signos combines a continuous glucose monitor (CGM) from Dexcom with an artificial intelligence platform. This setup provides personalized insights and real-time data to help users manage their weight. According to Sharam Fouladgar-Mercer, the co-founder and CEO of Signos, the goal is to create a solution that’s accessible for everyone, whether you want to lose five pounds or a hundred.
The obesity epidemic is a pressing issue, costing the U.S. healthcare system over $170 billion a year, with about 74% of Americans classified as overweight or obese, according to the CDC. With this backdrop, Signos aims to make a real impact.
Customers can choose plans costing $139 for three months or $129 for six months. While insurance currently doesn’t cover Signos for weight management, these prices are much lower than the typical $1,000 monthly cost for GLP-1 medications. Signos is actively working with insurers to expand coverage options.
The CGMs, which are small sensors worn on the upper arm, track glucose levels. This data syncs with the Signos app, where users can log food and exercise. The AI uses this information to give tailored recommendations, helping users understand how their bodies respond to what they eat and how they move.
A recent survey showed that nearly 65% of those trying to lose weight find monitoring food intake challenging. Signos addresses this need by making it easier to track glucose levels and make informed dietary choices. Fouladgar-Mercer noted that tens of thousands of people have already experimented with the system, and the company is prepared to scale up as demand grows.
With more people turning to technology for health management, shifting strategies may be on the rise. This approval opens doors for new conversations about weight loss and how innovative tools can aid those embarking on their weight management journeys.
For more insights into the impact of obesity and related health issues, you can visit the CDC’s obesity page.
Source link
Breaking News: Business,Health care industry,Pharmaceuticals,Biotech and Pharmaceuticals,Biotechnology,Business,Dexcom Inc,Novo Nordisk A/S,Novo Nordisk A/S,Eli Lilly and Co,United States,business news
